Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ: AGIO · IEX Real-Time Price · USD
33.14 1.19 (3.72%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap1.80B
Revenue (ttm)44.05M
Net Income (ttm)1.60B
Shares Out54.31M
EPS (ttm)24.95
PE Ratio1.33
Forward PE2.47
Dividendn/a
Ex-Dividend Daten/a
Volume520,182
Open32.10
Previous Close31.95
Day's Range31.34 - 33.26
52-Week Range29.21 - 62.16
Beta1.50
AnalystsBuy
Price Target58.25 (+75.8%)
Earnings DateNov 3, 2021

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which...

IndustryBiotechnology
IPO DateJul 24, 2013
CEOJacqualyn Fouse
Employees562
Stock ExchangeNASDAQ
Ticker SymbolAGIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 58.25, which is an increase of 75.77% from the latest price.

Price Target
$58.25
(75.77% upside)
Analyst Consensus: Buy

News

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company's Strategic Vision in Genetically Define...

– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February –

6 days ago - GlobeNewsWire

Robot Portfolio: Value in the Extreme

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

1 week ago - GuruFocus

4 Biotechs That Were Winners at ASH

Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.

Other symbols:BLUEBMYFMTX
2 weeks ago - The Motley Fool

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...

3 weeks ago - GlobeNewsWire

Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat in adults with pyruvate kinase (PK) deficiency. Data ...

1 month ago - Benzinga

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Bur...

– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency  Patients –

1 month ago - GlobeNewsWire

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers...

– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated –

1 month ago - GlobeNewsWire

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Impr...

– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients –

1 month ago - GlobeNewsWire

Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Agios Appoints Richa Poddar as Chief Commercial Officer

Darrin Miles to Depart Agios to Pursue a Chief Executive Officer Opportunity Darrin Miles to Depart Agios to Pursue a Chief Executive Officer Opportunity

2 months ago - GlobeNewsWire

Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3

Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.

2 months ago - Zacks Investment Research

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

– Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 –

2 months ago - GlobeNewsWire

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the co...

2 months ago - GlobeNewsWire

Agios To Present at September Investor Conferences

CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetical...

4 months ago - GlobeNewsWire

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

4 months ago - InvestorPlace

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.

4 months ago - Zacks Investment Research

Agios' Rare Anemia Drug Application Under FDA Priority Review

The FDA has accepted Agios Pharmaceuticals Inc's (NASDAQ: AGIO) marketing application seeking approval for mitapivat for pyruvate kinase (PK) deficiency. Under Priority Review designation, the agency's ...

4 months ago - Benzinga

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with...

-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --

4 months ago - GlobeNewsWire

Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress

Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.

5 months ago - Zacks Investment Research

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –

5 months ago - GlobeNewsWire

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that t...

6 months ago - GlobeNewsWire

Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug

Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.

6 months ago - Zacks Investment Research